Virpax Pharmaceuticals (VRPX) Institutional Ownership $0.22 -0.01 (-2.27%) As of 05/21/2025 03:54 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Virpax Pharmaceuticals (NASDAQ:VRPX)CurrentInstitutional OwnershipPercentage32.23%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$1.99MNumber ofInstitutional Sellers(last 12 months)0 Get VRPX Insider Trade Alerts Want to know when executives and insiders are buying or selling Virpax Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data VRPX Institutional Buying and Selling by Quarter Virpax Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails12/10/2024 Garden State Investment Advisory Services LLC57,300$40K0.0%N/A1.172% 11/15/2024 Garden State Investment Advisory Services LLC57,300$40K0.0%N/A1.172% 11/15/2023 Sabby Management LLC292,790$234K0.2%-26.8%2.500% 5/13/2022 Warberg Asset Management LLC17,710$39K0.0%N/A0.151% 11/17/2021 Altium Capital Management LP271,846$1.31M0.3%N/A2.320% 11/16/2021National Asset Management Inc.18,600$90K0.0%N/A0.159% 11/2/2021 Cambridge Investment Research Advisors Inc.19,420$93K0.0%N/A0.166% 9/17/2021 Virtu Financial LLC23,625$107K0.0%N/A0.468% 8/16/2021 Sabby Management LLC154,737$704K0.1%-22.6%3.120% 8/12/2021Saltoro Capital LP17,615$80K0.0%-34.8%0.355% 5/14/2021HN Saltoro Capital LP27,000$127K0.0%N/A0.546% (Data available from 1/1/2016 forward) VRPX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of VRPX shares? During the previous two years, the following institutional investors and hedge funds held shares of Virpax Pharmaceuticals shares: Sabby Management LLC ($234K), Garden State Investment Advisory Services LLC ($40K).Learn more on VRPX's institutional investors. What percentage of Virpax Pharmaceuticals stock is owned by institutional investors? 32.23% of Virpax Pharmaceuticals stock is owned by institutional investors. Learn more on VRPX's institutional investor holdings. Which institutional investors have been buying Virpax Pharmaceuticals stock? The following institutional investors have purchased Virpax Pharmaceuticals stock in the last 24 months: Garden State Investment Advisory Services LLC ($114.60K). How much institutional buying is happening at Virpax Pharmaceuticals? Institutional investors have bought a total of 114,600 shares in the last 24 months. This purchase volume represents approximately $1.99M in transactions. Which Virpax Pharmaceuticals major shareholders have been selling company stock? The following institutional investors have sold Virpax Pharmaceuticals stock in the last 24 months: Sabby Management LLC ($107.21K). How much institutional selling is happening at Virpax Pharmaceuticals? Institutional investors have sold a total of 107,210 shares in the last 24 months. This volume of shares sold represents approximately $21.44M in transactions. Related Companies VIRX Major Shareholders ATXI Major Shareholders TFFP Major Shareholders VINC Major Shareholders NCNA Major Shareholders UPC Major Shareholders SMFL Major Shareholders ADTX Major Shareholders This page (NASDAQ:VRPX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
